The HOXB13:IL7BR expression index is a prognostic factor in early-stage breast cancer
The HOXB13:IL7BR expression index is a prognostic factor in early-stage breast cancer
复制标题
DOI：
10.1200/jco.2006.06.6944
复制
发表时间：
2006-10-01
影响因子：
45.3
通讯作者：
Erlander, Mark G.
中科院分区：
文献类型：
--
作者：
Ma, Xiao-Jun;Hilsenbeck, Susan G.;Erlander, Mark G.
我们之前发现了三个基因HOXB13， IL17BR和CHDH，特别是HOXB13:IL17BR比值指数，可以强烈预测接受他莫昔芬单药治疗的乳腺癌患者的临床预后。需要在更大的独立患者队列中进行确认，以充分验证其临床效用。方法采用实时聚合酶链反应法测定566例未经治疗和286例他莫昔芬治疗的852例福尔马林固定石蜡包埋乳腺癌患者中HOXB13、IL17BR、CHDH、雌激素受体（ER）和孕激素受体（PR）的表达。采用Cox比例风险回归模型分析基因表达和临床变量与无复发生存率（RFS）的相关性。结果ser和PR mRNA检测结果与免疫组化结果一致。在整个队列中，hoxb13的表达与较短的RFS相关（P = 0.008）， IL17BR和CHDH的表达与较长的RFS相关（P = 0.008）
PurposeWe previously identified three genes, HOXB13, IL17BR and CHDH, and the HOXB13:IL17BR ratio index in particular, that strongly predicted clinical outcome in breast cancer patients receiving tamoxifen monotherapy. Confirmation in larger independent patient cohorts was needed to fully validate their clinical utility.Patients and MethodsExpression of HOXB13, IL17BR, CHDH, estrogen receptor (ER) and progesterone receptor (PR) were quantified by real-time polymerase chain reaction in 852 formalin-fixed, paraffin-embedded primary breast cancers from 566 untreated and 286 tamoxifen-treated breast cancer patients. Gene expression and clinical variables were analyzed for association with relapse-free survival (RFS) by Cox proportional hazards regression models.ResultsER and PR mRNA measurements were in close agreement with immunohistochemistry. In the entire cohort, expression of HOXB 13 was associated with shorter RFS (P =.008), and expression of IL17BR and CHDH was associated with longer RFS (P